Article

Differential Benefit of Immune Checkpoint Blockade by<i>KRAS</i>Mutation Status in Metastatic Lung Adenocarcinoma: Validation from an Extended Swedish Cohort

2025-04-10

Abstract excerpt

<h4>Introduction</h4> Immune checkpoint blockade (ICB) is a standard first-line treatment for advanced-stage non-small cell lung cancer (NSCLC) without actionable oncogenic alterations. KRAS mutations, prevalent in 30–40% of Western lung adenocarcinomas, currently lack targeted first-line therapies. This study aimed to assess the predictive value of KRAS mutations for clinical outcomes following ICB, validating pr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5c7207c0-af00-5632-8636-48a5b7069613
DOI: 10.1101/2025.04.09.25325505

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Differential Benefit of Immune Checkpoint Blockade by<i>KRAS</i>Mutation Status in Metastatic Lung Adenocarcinoma: Validation from an Extended Swedish CohortDOI 10.1101/2025.04.09.25325505Read

<i>KRAS</i>mutations impact clinical outcome in metastatic non-small cell lung cancerSemantic proximity Read

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity Read

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity Read

Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancerSemantic proximity Read

Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.Semantic proximity Read

Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients.Semantic proximity Read

Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.Semantic proximity Read

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.Semantic proximity Read

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.Semantic proximity Read

Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.Semantic proximity Read

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCSemantic proximity Read

A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.Semantic proximity Read